Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331276

Institution ID

3331276

Institution full name and acronym

Brigham and Women's Hospital

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A description of oral and non-insulin injected hypoglycemic therapy utilization patterns including initiation, switching, and discontinuation (Non-insulin hypoglycemic therapy utilization)
A description of warfarin and new oral anticoagulant utilization patterns including initiation, switching, and discontinuation: Phase 3 of the BI/BWH Pradaxa study program (Anticoagulant utilization pattern)
A retrospective cohort study with chart review to assess the management of major bleeding events in NVAF patients treated with dabigatran etexilate
Active surveillance research program for the assessment of the safety and the effectiveness of linagliptin
Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
Delayed Denosumab Injections and Fractures Risk Among Subjects with Osteoporosis
Empagliflozin effectiveness in a real-world population replicating the DECLARE - TIMI58 trial
Non-interventional study on the effectiveness and safety of Empagliflozin compared with DPP-4 inhibitors in patients with type 2 diabetes in the United States
Observational Studies to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine (F1J-MC-B057)
Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
Validation of predictors for oral anticoagulant medication choice using EMR data